Category

Glioblastoma (“GBM”)

VBI Vaccines Provides Update on Part A of Ongoing Phase 1/2a Study Demonstrating Overall Survival Benefit for VBI-1901 Vaccine Responders in Recurrent GBM Patients

By | Glioblastoma ("GBM"), Press Releases
Updated overall survival (OS) data for Part A demonstrated 83% 12-month OS rate among vaccine responders vs. 33% for non-responders Vaccine responders saw a 6.25-month improvement in median OS compared to non-responders VBI-1901 continues to be safe and well-tolerated, with...
Read More

VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Phase 2a Study of Cancer Vaccine Candidate, VBI-1901, in Combination with GSK’s AS01B Adjuvant System

By | Glioblastoma ("GBM"), Press Releases
The two-arm Phase 2a study is expected to enroll 20 first-recurrent GBM patients to receive VBI’s cancer vaccine candidate, VBI-1901, in combination with either GM-CSF or AS01B Initial immunologic data from the VBI-1901 with AS01B study arm expected Q4 2020...
Read More

VBI Vaccines Presents Early GBM Tumor Response and Immunologic Data from Part B of Ongoing Phase 1/2a Study of VBI-1901 at the 2019 SNO Annual Meeting

By | Conferences, Glioblastoma ("GBM"), Press Releases
33% reduction in tumor size observed in one patient in Part B – reduction sustained through two consecutive MRI scans 6-month overall survival (OS) now available for Part A demonstrated benefit for vaccine responders (100%) vs. non-responders (63%) VBI Vaccines...
Read More

VBI Vaccines to Present Initial Phase 1/2a Part B Data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting

By | Conferences, Glioblastoma ("GBM"), Press Releases
VBI Vaccines Inc. (NASDAQ: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the Company’s abstract titled, “Interim Results of the Extension Phase of a Phase I/IIa Trial of a Therapeutic CMV Vaccine...
Read More

VBI Vaccines Announces Poster Presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop

By | Conferences, Cytomegalovirus ("CMV"), Glioblastoma ("GBM"), Press Releases
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that David Anderson, Ph.D., Chief Scientific Officer, will present the poster, “CMV gB/pp65 eVLPs Formulated with GM-CSF as a Therapeutic Vaccine...
Read More